<DOC>
	<DOCNO>NCT00351169</DOCNO>
	<brief_summary>To evaluate efficacy safety quetiapine fumarate sustain release ( Seroquel SR ) treatment Major Depressive Disorder . PLEASE NOTE : Seroquel SR Seroquel XR refer formulation . The SR designation change XR consultation FDA .</brief_summary>
	<brief_title>Efficacy Seroquel SR Combination With Antidepressant Treatment Major Depressive Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<mesh_term>Citalopram</mesh_term>
	<criteria>Male female age 18 65 year A document diagnosis major depressive disorder Patients DSM IV Axis I disorder MDD within 6 month enrolment Patients diagnosis DSM IV Axis II disorder major impact patient 's current psychiatric status Patients whose current episode depression exceed 12 month less 4 week prior enrolment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2007</verification_date>
	<keyword>Major Depressive Disorder</keyword>
	<keyword>MDD</keyword>
</DOC>